Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating Pembrolizumab Plus Lenvatinib in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

 According to results of  2 planned interim analyses conducted over an 11-month period, researchers have demonstrated  that pembrolizumab plus lenavatinib provides patients with a statistically significant improvement in PFS and ORR compared to pembrolizumab alone but, does not provide improvement in OS. Due to these results the study has been closed.

Access the full article to read more here.